Table 1 Baseline and clinical characteristics in 163 patients

Age: median (years), range

69

(23–89)

Gender: female/male

68/95

(42%/58%)

 Upper GI

38

(23%)

  Oesophagus

10

(6%)

  Gastrooesophageal junction (GEJ)

15

(9%)

  Stomach

13

(8%)

 Pancreas

28

(18%)

  Pancreas

28

(18%)

 Lower GI

64

(39%)

  Small intestine

3

(2%)

  Colorectal

61

(37%)

 Cancer unknown primary (CUP) (predominantly with abdominal metastases)

33

(20%)

 Localised

15

(9%)

 Regional

36

(22%)

 Disseminated

112

(69%)

 WHO Performance Status

147

(90%)

  0

61

(41%)

  1

48

(33%)

  2

22

(15%)

   > 2

16

(11%)

 Treatment

142

(87%)

 Surgery

71

(44%)

  Primary tumour

61

(86%)

  Metastasis

19

(27%)

  Operation at diagnosis

56

(79%)

Curative intent

53

(75%)

 Chemotherapy

119

(73%)

  Neoadjuvant chemotherapy

14

(12%)

  Adjuvant chemotherapy

28

(24%)

  Palliative chemotherapy

103

(87%)

 Radiotherapy^a

46

(28%)

  Primary tumour

6

(13%)

  Metastasis

41

(89%)

 PRRT

2

(1%)

 Lactate dehydrogenase (LDH), serum level

143

(88%)

  Normal

67

(47%)

   < 2 UNL^b

52

(36%)

   > 2 UNL

24

(17%)

 Chromogranin A (CgA), plasma level

112

(69%)

  Normal

61

(55%)

   < 2 UNL

20

(18%)

   > 2 UNL

31

(28%)